ZYME

Zymeworks Inc. Common Stock

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.

Zymeworks Inc. Common Stock (ZYME) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Growth (D+).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C+
Factor Score 2.7 / 5.0
Growth
D+
Factor Score 1.7 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.3
Rev Growth YoY -91.1%
Gross Margin -67.0%
Price Return 3M -20.3%
Price Return 12M 69.6%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 19.9
ROE -42.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-02 C+ (2.7) D+ (1.7) D+ (1.8) C (2.4) C- (1.9) C- (2.1)
2026-07-29 C+ (2.5) A+ (5.0) D+ (1.7) C (2.2) D+ (1.5) C+ (2.6)
2022-06-30 C (2.3) A+ (5.0) D+ (1.8) C (2.2) D (1.5) C+ (2.6)
2022-03-31 D- (0.9) A+ (5.0) D+ (1.8) C (2.2) D (1.5) C (2.3)
2021-12-31 C+ (2.6) C (2.4) D+ (1.8) C (2.2) D (1.5) C- (2.1)
Page 1 of 2